Market Overview:
The global histone deacetylase inhibitors market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of cancer, rising demand for novel therapies, and growing focus on targeted therapies. Based on type, the global histone deacetylase inhibitors market is segmented into belinostat, romidepsin, and chidamide. Of these, belinostat dominates the market owing to its high efficacy and safety profile. Based on application, the global histone deacetylase inhibitors market is segmented into cancer treatment, inflammatory diseases (such as Crohn’s disease), and other diseases (such as psoriasis). Cancer treatment currently accounts for a major share of this market.
Product Definition:
Histone deacetylase inhibitors are a class of drugs that stop or slow the action of histone deacetylases. Histone deacetylases play a role in gene regulation, and inhibiting their action can result in changes to gene expression. Histone deacetylase inhibitors are used as cancer treatments and for other conditions such as psoriasis.
Belinostat:
Belinostat is a novel oral HDAC inhibitor developed by Arena Pharmaceuticals. It was approved in China in 2016 and globally in 2017. The drug has shown positive results for the treatment of multiple myeloma, prostate cancer, and gastric cancer cells lines.
HDAC inhibitors are known to deacetylate Histone H3 (H3) which leads to inhibition of nuclear transcription factor kB (NF-kB).
Romidepsin:
Romidepsin is a naturally occurring compound isolated from the fungus Romalea michelii. It was first discovered by accident in 1960 when researchers were studying for the synthesis of vitamin E. The compound has been found to be effective in preventing damage to cells caused by radiation and other chemical agents. Romidepsin has also been found to have anesthetic properties, which can be used for treating patients recovering from surgery or suffering from pain due to cancer or arthritis.
Application Insights:
The cancer treatment segment dominated the global histone deacetylase inhibitors market in 2017 and is expected to maintain its dominance over the forecast period. This can be attributed to increasing incidence of various types of cancers, rising awareness about available treatments, and growing adoption of these drugs as compared with other therapeutic options.
For instance, Acumed Biosciences Corporation's (ACUMed) lead drug candidate, CNP-SB01 for the treatment of solid tumors was granted Fast Track status by U.S. FDA in January 2018 for advanced non-small cell lung cancer indication only; this is a rare example where a company has an approved product pipeline but no commercialized products yet. However, companies such as Pfizer Inc., are working on new drug development initiatives based on HDAC inhibition for various indications including cancer which may provide lucrative opportunities in near future.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of key players, high R&D investment by companies, and availability of effective treatment for various diseases. In addition, increasing prevalence of cancer is expected to drive growth over the forecast period. For instance, according to statistics published by American Cancer Society in 2018, 1 out of 6 men and 1 out of 4 women will be diagnosed with cancer during their lifetime in U.S.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising disposable income coupled with growing awareness about available treatments among patients & physicians especially in emerging countries such as China & India which are majorly target population for HDAC inhibitors such as belinostat & romidepsin respectively).
Growth Factors:
- Increasing prevalence of cancer: The increasing prevalence of cancer is one of the key growth drivers for histone deacetylase inhibitors market. According to the World Health Organization (WHO), in 2012, there were 14 million new cases of cancer and 8.2 million deaths due to cancer worldwide. This number is expected to increase by about 70% over the next two decades, accounting for 21 million new cases and 13 million deaths by 2030. Histone deacetylase inhibitors are used as a treatment option for various types of cancers such as breast cancer, colorectal cancer, prostate cancer, pancreatic ductal adenocarcinoma (PDA), non-small cell lung carcinoma (NSCLC), etc., owing to their ability to inhibit tumor growth and metastasis.
- Rising demand for targeted therapies: The growing demand for targeted therapies is another major factor driving the histone deacetylase inhibitors market growth globally. Histone deacetylase inhibitors are being increasingly used as monotherapy or in combination with other drugs owing to their ability to specifically target tumor cells without affecting normal cells surrounding them. This helps reduce adverse effects associated with traditional chemotherapy regimens and improve patient outcomes significantly..
Scope Of The Report
Report Attributes
Report Details
Report Title
Histone Deacetylase Inhibitors Market Research Report
By Type
Belinostat, Romidepsin, Chidamide
By Application
Cancer Treatment, Inflammatory Diseases, Other Diseases
By Companies
Acetylon Pharmaceuticals, Shenzhen Chipscreen Biosciences, Spectrum Pharmaceuticals, Adooq Bioscience, Crystal Genomics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
128
Number of Tables & Figures
90
Customization Available
Yes, the report can be customized as per your need.
Global Histone Deacetylase Inhibitors Market Report Segments:
The global Histone Deacetylase Inhibitors market is segmented on the basis of:
Types
Belinostat, Romidepsin, Chidamide
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer Treatment, Inflammatory Diseases, Other Diseases
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Acetylon Pharmaceuticals
- Shenzhen Chipscreen Biosciences
- Spectrum Pharmaceuticals
- Adooq Bioscience
- Crystal Genomics
Highlights of The Histone Deacetylase Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Belinostat
- Romidepsin
- Chidamide
- By Application:
- Cancer Treatment
- Inflammatory Diseases
- Other Diseases
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Histone Deacetylase Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Histone deacetylase inhibitors (HDAC inhibitors) are a class of drugs that inhibit the activity of histone deacetylases. Histone deacetylases are enzymes that remove acetyl groups from histones, which can lead to changes in the structure and function of proteins. HDAC inhibitors have been shown to be effective in treating a variety of diseases, including cancer, Crohn's disease, and psoriasis.
Some of the key players operating in the histone deacetylase inhibitors market are Acetylon Pharmaceuticals, Shenzhen Chipscreen Biosciences, Spectrum Pharmaceuticals, Adooq Bioscience, Crystal Genomics.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Histone Deacetylase Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Histone Deacetylase Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Histone Deacetylase Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Histone Deacetylase Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Histone Deacetylase Inhibitors Market Size & Forecast, 2020-2028
4.5.1 Histone Deacetylase Inhibitors Market Size and Y-o-Y Growth
4.5.2 Histone Deacetylase Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Belinostat
5.2.2 Romidepsin
5.2.3 Chidamide
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Cancer Treatment
6.2.2 Inflammatory Diseases
6.2.3 Other Diseases
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Histone Deacetylase Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Histone Deacetylase Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Belinostat
9.6.2 Romidepsin
9.6.3 Chidamide
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Cancer Treatment
9.10.2 Inflammatory Diseases
9.10.3 Other Diseases
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Belinostat
10.6.2 Romidepsin
10.6.3 Chidamide
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Cancer Treatment
10.10.2 Inflammatory Diseases
10.10.3 Other Diseases
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Belinostat
11.6.2 Romidepsin
11.6.3 Chidamide
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Cancer Treatment
11.10.2 Inflammatory Diseases
11.10.3 Other Diseases
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Belinostat
12.6.2 Romidepsin
12.6.3 Chidamide
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Cancer Treatment
12.10.2 Inflammatory Diseases
12.10.3 Other Diseases
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Belinostat
13.6.2 Romidepsin
13.6.3 Chidamide
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Cancer Treatment
13.10.2 Inflammatory Diseases
13.10.3 Other Diseases
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Histone Deacetylase Inhibitors Market: Competitive Dashboard
14.2 Global Histone Deacetylase Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Acetylon Pharmaceuticals
14.3.2 Shenzhen Chipscreen Biosciences
14.3.3 Spectrum Pharmaceuticals
14.3.4 Adooq Bioscience
14.3.5 Crystal Genomics
